UNSPSC 51273014: Alfentanil hydrochloride monohydrate

This classification denotes an opioid receptor agonist and opioid with the molecular formula C21H32N6O3.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 11S92G0TIW, chemically known as n-(1-(2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)-ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide monohydrochloride monohydrate, but more generally known as alfentanil hydrochloride monohydrate, which bears US NIH Compound Identifier 64762.

European Medicines Agency schedules alfentanil hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05317MIG. Most nations, for tariff purposes, schedule alfentanil hydrochloride monohydrate under HS 29333300. SMILES: CCC(=O)N(C1CCCCC1)C2(CCN(CC2)CCN3C(=O)N(NN3)CC)COC.O.CL.

UNSPSC 51273014 Alfentanil hydrochloride monohydrate is a Commodity code that captures pharmaceutical supply procurement by state and local health authorities, though the recent opportunities block shows minimal direct activity under this specific code. The three recent solicitations posted across the code show state and local governments buying naloxone (an opioid antagonist), generic pharmaceuticals, and OTC products through competitive and cooperative purchasing vehicles rather than alfentanil itself. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The nature of recent work spans acute-care pharmaceutical supply (naloxone for overdose response), direct-to-manufacturer prescription programs, and bulk generic pharmaceutical distribution to state and local healthcare facilities across multiple states.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's cooperative purchasing vehicle extending to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer pharmacy programs for self-insured health plans and state agencies; and MMCAP's RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson with contract effectiveness July 1, 2026. The code shows limited direct procurement of alfentanil hydrochloride monohydrate specifically; recent activity skews toward broader pharmaceutical supply and overdose-response products rather than controlled synthetic opioids.